In the dark: Johnson & Johnson’s Animas
Johnson & Johnson’s Animas subsidiary seemed ahead of the curve in 2013 when it was testing its 1st-gen closed loop insulin delivery system, but the company hasn’t updated on the status of the device since then.
The company was reportedly developing an Animas pump with built-in hypoglycemia-hyperglycemia minimizer algorithm, and seemed to be ahead of competitor Medtronic in the early stages of development, producing 2 feasibility studies of the device.
But Animas has gone silent on the project. Earlier this year, Johnson & Johnson was said to be considering “strategic options” for its diabetes businesses, including LifeScan, Calibra Medical and Animas brands.
“Strategic options may include the formation of operating partnerships, joint ventures or strategic alliances, a sale of the businesses, or other alternatives either separately or together,” the healthcare conglomerate said in reporting its 4th-quarter and full-year earnings in late January. “All options will be evaluated to determine the best opportunity to drive future growth and maximize shareholder value. There can be no assurance that this process will result in any transaction or other strategic alternative of any kind.”
Diabetes sales were off for both periods, sliding -3.8% to $462 million during Q4 and -7.2% to $1.79 billion for full-year 2016.